Genetic and Epigenetic Factors
Genetic predisposition and epigenetic modifications provide the constitutional vulnerability upon which environmental triggers act to produce ME/CFS. While the condition is clearly not a simple Mendelian disorder, converging evidence from family studies, twin research, and molecular genetics demonstrates that heritable factors substantially influence disease susceptibility. The 2025 DecodeME genome-wide association study (n=21,620) represents a watershed moment in understanding the polygenic architecture underlying ME/CFS (DecodeME Consortium, Ponting, et al. 2025).
Understanding genetic and epigenetic contributions illuminates why only a subset of individuals develop chronic illness following viral infections, traumatic events, or other precipitating factors. The immune abnormalities detailed in Chapter Immune System Dysfunction—including NK cell dysfunction, T cell exhaustion, and cytokine dysregulation—reflect genetic variants in immune system genes and epigenetic reprogramming following chronic antigenic stimulation. Similarly, the metabolic dysfunction described in Chapter Energy Metabolism and Mitochondrial Function arises in part from genetic variants affecting mitochondrial function and oxidative metabolism, amplified by epigenetic silencing of metabolic genes. Neurological manifestations (Chapter Neurological and Neurocognitive Dysfunction) may stem from genetic influences on ion channels such as TRPM3, neurotransmitter systems, and blood-brain barrier integrity. Cardiovascular and autonomic dysfunction (Chapter Cardiovascular Dysfunction) shows familial clustering consistent with inherited susceptibility to orthostatic intolerance and dysautonomia.
This chapter examines the genetic architecture of ME/CFS susceptibility, epigenetic modifications that may perpetuate chronic illness, and patterns of gene expression dysregulation across multiple physiological systems. Understanding these constitutional factors is essential for developing personalized therapeutic approaches, identifying at-risk individuals, and elucidating the fundamental mechanisms that distinguish those who recover from acute illness from those who progress to chronic disease.
For patients: read the heritability and gene-environment sections to understand why ME/CFS is not your fault and why triggers matter. Do not interpret risk scores clinically — none is validated.
For caregivers: read the heritability section to understand the constitutional-vulnerability framing. The GWAS detail is research-oriented and can be skimmed.
For clinicians: read the heritability and candidate-gene sections, especially the MTHFR observation, for pharmacogenomic relevance. The GWAS loci currently have no clinical testing value.
For researchers: read the DecodeME, Maccallini meta-GWAS, and Kerrebijn sections for the brain-first architecture, plus the computable-analyses section for untested hypotheses using existing data.